ReviewTherapeutic drug monitoring2010
Assays for measuring rivaroxaban: their suitability and limitations.
Review in Therapeutic drug monitoring, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.British journal of clinical pharmacology · 2014Trial
- Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.British journal of clinical pharmacology · 2014Trial
- Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.British journal of clinical pharmacology · 2013Trial
- Engineering Host-Guest Interactions for Next-Generation Heparin Biosensors.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2021Article
- Innovative Three-Step Microwave-Promoted Synthesis ofMolecules (Basel, Switzerland) · 2020Article
- Diagnostic accuracy of thromboelastometry and its correlation with the HPLC-MS/MS quantification test.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2019Article
- Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update.Indian journal of anaesthesia · 2019Review
- Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature.World journal of clinical cases · 2019Article
- Article
- Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization.European journal of clinical pharmacology · 2018Observational
- Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis.Blood advances · 2018Article
- Article
- In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.Blood transfusion = Trasfusione del sangue · 2016Article
- Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2016Review
- New oral anticoagulants - a practical guide.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2015Article
- Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.British journal of clinical pharmacology · 2015Article
- A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample.Journal of thrombosis and thrombolysis · 2015Article
- The role of novel anticoagulants in the management of venous thromboembolic disease.Current treatment options in cardiovascular medicine · 2014Article
- Safety of new oral anticoagulant drugs: a perspective.Therapeutic advances in drug safety · 2014Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several new oral anticoagulants such as rivaroxaban (which targets Factor Xa) and dabigatran etexilate (which targets thrombin) are in advanced stages of clinical development and are already available for clinical use in some countries. Although these agents do not require routine coagulation monitoring, assays to assess the level of anticoagulation may be of assistance in certain circumstances such as in case of overdose, in patients with a hemorrhagic or thromboembolic event during treatment, or to assess compliance. Moreover, the influence of the new oral anticoagulants on routine coagulation tests must be recognized. The prothrombin time is not suitable for rivaroxaban measurement for several reasons, and the routinely used international normalized ratio for monitoring the vitamin K antagonists cannot be applied to rivaroxaban. Development of universal assays is challenging because the new oral anticoagulants have different targets, and even those with the same target have variable effects on routine coagulation assays. Focusing on rivaroxaban, there is emerging evidence that an anti-Factor Xa assay that uses rivaroxaban-containing plasma calibrators may provide the optimal method for determining plasma rivaroxaban concentrations.
Indexed as
Identifiers
20844464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.